Related Experiment Video

Updated: Jul 14, 2026

Quantitative Mass Spectrometric Profiling of Cancer-cell Proteomes Derived From Liquid and Solid Tumors
08:08

Quantitative Mass Spectrometric Profiling of Cancer-cell Proteomes Derived From Liquid and Solid Tumors

Published on: February 27, 2015

Proteomic analysis of bone cancer: a review of current and future developments

Sudeepa Bhattacharyya1, Stephanie Byrum, Eric R Siegel

  • 1University of Arkansas for Medical Sciences, Department of Orthopaedic Surgery, Center for Orthopaedic Research, Barton Research Institute, Little Rock, AR 72205, USA. bhattacharyyasudeepa@uams.edu

Expert Review of Proteomics
|June 8, 2007
PubMed

Insights

Sophisticated proteomic technologies are advancing the study of bone cancers, including myeloma and bone metastases. Further research is needed to fully apply these powerful tools to understand and treat skeletal malignancies.

Area of Science:

  • Biochemistry
  • Oncology
  • Proteomics

Background:

  • Proteomic approaches offer deep insights into protein dynamics, crucial for identifying cancer biomarkers and therapeutic targets.
  • Bone cancers, including myeloma and bone metastases from breast and prostate cancers, remain under-investigated using proteomic techniques.
  • Recent technological advancements are enabling a deeper understanding of skeletal cancer biology.

Purpose of the Study:

  • To review recent advances in proteomic technologies relevant to skeletal cancers.
  • To highlight the application of proteomics in understanding bone cancer.
  • To identify future research directions for applying proteomics to skeletal malignancy.

Main Methods:

  • Review of recent literature on proteomic technologies and their application to bone cancers.
  • Analysis of advancements in protein expression, localization, modification, and interaction studies.
  • Focus on technologies applicable to myeloma, osteosarcoma, and bone metastases.

Main Results:

  • Proteomics has identified numerous potential therapeutic targets and biomarkers in cancer.
  • Significant under-utilization of advanced proteomic methods in skeletal cancer research has been noted.
  • Emerging proteomic technologies are poised to revolutionize bone cancer investigation.

Conclusions:

  • Proteomic technologies are crucial for advancing the understanding of bone cancers.
  • Further adaptation and application of these technologies are necessary to address skeletal malignancies.
  • Future work should focus on interrogating the skeletal consequences of cancer using proteomics.

More Related Videos

Murine Hind Limb Long Bone Dissection and Bone Marrow Isolation07:17

Murine Hind Limb Long Bone Dissection and Bone Marrow Isolation

Published on: April 14, 2016

Models of Bone Metastasis08:49

Models of Bone Metastasis

Published on: September 4, 2012

Related Concept Videos

Proteomics01:33

Proteomics

A proteome is the entire set of proteins that a cell type produces. We can study proteomes using the knowledge of genomes because genes code for mRNAs, and the mRNAs encode proteins. Although mRNA analysis is a step in the right direction, not all mRNAs are translated into proteins.
Proteomics is the study of proteomes' function. It involves the large-scale systematic study of the proteome to denote the protein complement expressed by a genome. Scientist Mark Wilkins coined the term proteomics...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...